Pulmatrix (NASDAQ: PULM) is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology, according to the company’s website (see here: www.Pulmatrix.com). SNNLive caught up with Robert Clarke, CEO of Pulmatrix, Inc. at the Marcum MicroCap Conference 2016 in New York City, NY.
In this video interview, Mr. Clarke and our host discuss the following topics:
- Overview of Pulmatrix, Inc.
- Clinical Development
- Discusses iSPERSE™ technology
- Target indications
- Milestones for 2016
For more information about Pulmatrix, Inc., please visit: www.Pulmatrix.com
The interview may contain forward-looking statements about Pulmatrix, Inc. See Pulmatrix's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions